{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T22:05:46Z","timestamp":1794089146208,"version":"4.8.0"},"reference-count":91,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Sciences"],"abstract":"<jats:p>Arterial hypertension remains the major cardiovascular risk worldwide. It is estimated that under 50 years of age one in every three adults is hypertensive while beyond the age of 50 the prevalence is almost 50% globally. The latest World Health Organization (WHO) Global Report on Hypertension indicated that the global number of hypertensive patients almost doubled in the last three decades, with related increasing deaths, disability, and costs annually. Because of this global increase, early diagnosis and timely treatment is of great importance. However, based on the WHO Global Report, it is estimated that up to 46% of individuals were never diagnosed. Of those diagnosed, less than 50% were on treatment, with nearly half among these at target according to the current guidelines. It is also important to note that an increasing number of hypertensive patients, despite the use of three or more drugs, still do not achieve a blood pressure normalization, thus defining the clinical scenario of resistant hypertension (RH). This condition is associated to a higher risk of hypertension-mediated organ damage and hospitalization due to acute cardiovascular events. Current guidelines recommend a triple combination therapy (renin angiotensin system blocking agent + a thiazide or thiazide-like diuretic + a dihydropyridinic calcium-channel blocker) to all patients with RH. Beta-blockers and mineralocorticoid receptor antagonists, alone or in combination, should be also considered based on concomitant conditions and potential contraindications. Finally, the renal denervation is also proposed in patients with preserved kidney function that remain hypertensive despite the use of maximum tolerated medical treatment. However, the failure of this procedure in the long term and the contraindication in patients with kidney failure is a strong call for a new therapeutic approach. In the present review, we will discuss the pharmacological novelties to come for the management of hypertension and RH in the next future.<\/jats:p>","DOI":"10.3390\/medsci12040053","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T06:00:57Z","timestamp":1728021657000},"page":"53","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Increasing Problem of Resistant Hypertension: We\u2019ll Manage till Help Comes!"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7824-6033","authenticated-orcid":false,"given":"Francesco","family":"Natale","sequence":"first","affiliation":[{"name":"Vanvitelli Cardiology and Intensive Care Unit, Monaldi Hospital, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Franzese","sequence":"additional","affiliation":[{"name":"Vanvitelli Cardiology and Intensive Care Unit, Monaldi Hospital, 80131 Naples, Italy"},{"name":"Department of Translational Medical Sciences, Section of Cardiology, University of Campania Luigi Vanvitelli, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ettore","family":"Luisi","sequence":"additional","affiliation":[{"name":"Vanvitelli Cardiology and Intensive Care Unit, Monaldi Hospital, 80131 Naples, Italy"},{"name":"Department of Translational Medical Sciences, Section of Cardiology, University of Campania Luigi Vanvitelli, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Mollo","sequence":"additional","affiliation":[{"name":"Vanvitelli Cardiology and Intensive Care Unit, Monaldi Hospital, 80131 Naples, Italy"},{"name":"Department of Translational Medical Sciences, Section of Cardiology, University of Campania Luigi Vanvitelli, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Marotta","sequence":"additional","affiliation":[{"name":"Vanvitelli Cardiology and Intensive Care Unit, Monaldi Hospital, 80131 Naples, Italy"},{"name":"Department of Translational Medical Sciences, Section of Cardiology, University of Campania Luigi Vanvitelli, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achille","family":"Solimene","sequence":"additional","affiliation":[{"name":"Vanvitelli Cardiology and Intensive Care Unit, Monaldi Hospital, 80131 Naples, Italy"},{"name":"Department of Translational Medical Sciences, Section of Cardiology, University of Campania Luigi Vanvitelli, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5415-1953","authenticated-orcid":false,"given":"Saverio","family":"D\u2019Elia","sequence":"additional","affiliation":[{"name":"Cardiology Unit, AOU Luigi Vanvitelli, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3590-6983","authenticated-orcid":false,"given":"Paolo","family":"Golino","sequence":"additional","affiliation":[{"name":"Vanvitelli Cardiology and Intensive Care Unit, Monaldi Hospital, 80131 Naples, Italy"},{"name":"Department of Translational Medical Sciences, Section of Cardiology, University of Campania Luigi Vanvitelli, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3802-7052","authenticated-orcid":false,"given":"Giovanni","family":"Cimmino","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, Section of Cardiology, University of Campania Luigi Vanvitelli, 80131 Naples, Italy"},{"name":"Cardiology Unit, AOU Luigi Vanvitelli, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension","volume":"41","author":"Mancia","year":"2023","journal-title":"J. Hypertens."},{"key":"ref_2","first-page":"1076","article-title":"Revisiting Cardiovascular Benefits of Blood Pressure Reduction in Primary and Secondary Prevention: Focus on Targets and Residual Risk-A Systematic Review and Meta-Analysis","volume":"81","author":"Manta","year":"2024","journal-title":"Hypertension"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"McEvoy, J.W., McCarthy, C.P., Bruno, R.M., Brouwers, S., Canavan, M.D., Ceconi, C., Christodorescu, R.M., Daskalopoulou, S.S., Ferro, C.J., and Gerdts, E. (2024). 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur. Heart J., ehae178.","DOI":"10.1093\/eurheartj\/ehae178"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e002155","DOI":"10.1161\/JAHA.115.002155","article-title":"Residual Cardiovascular Risk in Individuals on Blood Pressure-Lowering Treatment","volume":"4","author":"Lieb","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11906-023-01282-0","article-title":"Resistant Hypertension: Disease Burden and Emerging Treatment Options","volume":"26","author":"Flack","year":"2024","journal-title":"Curr. Hypertens. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40292-024-00634-4","article-title":"Systematic Review Article: New Drug Strategies for Treating Resistant Hypertension-the Importance of a Mechanistic, Personalized Approach","volume":"31","author":"Nardoianni","year":"2024","journal-title":"High Blood Press. Cardiovasc. Prev. Off. J. Ital. Soc. Hypertens."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2147\/VHRM.S138599","article-title":"Managing resistant hypertension: Focus on mineralocorticoid-receptor antagonists","volume":"13","author":"Modolo","year":"2017","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s11906-022-01185-6","article-title":"An Update on Refractory Hypertension","volume":"24","author":"Matanes","year":"2022","journal-title":"Curr. Hypertens. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1161\/01.HYP.0000094221.86888.AE","article-title":"Influence of Weight Reduction on Blood Pressure","volume":"42","author":"Neter","year":"2003","journal-title":"Hypertension"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e016804","DOI":"10.1161\/JAHA.120.016804","article-title":"Nonpharmacologic Interventions for Reducing Blood Pressure in Adults with Prehypertension to Established Hypertension","volume":"9","author":"Fu","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"643S","DOI":"10.1093\/ajcn\/65.2.643S","article-title":"Randomized trials of sodium reduction: An overview","volume":"65","author":"Cutler","year":"1997","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/jch.14562","article-title":"Effectiveness of salt substitute on cardiovascular outcomes: A systematic review and meta-analysis","volume":"24","author":"Tsai","year":"2022","journal-title":"J. Clin. Hypertens."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"f1378","DOI":"10.1136\/bmj.f1378","article-title":"Effect of increased potassium intake on cardiovascular risk factors and disease: Systematic review and meta-analyses","volume":"346","author":"Aburto","year":"2013","journal-title":"BMJ"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/eurjpc\/zwab007","article-title":"Exercise intensity assessment and prescription in cardiovascular rehabilitation and beyond: Why and how: A position statement from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology","volume":"29","author":"Hansen","year":"2022","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e004473","DOI":"10.1161\/JAHA.112.004473","article-title":"Exercise Training for Blood Pressure: A Systematic Review and Meta-analysis","volume":"2","author":"Cornelissen","year":"2013","journal-title":"J. Am. Heart Assoc."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1016\/S2468-2667(17)30003-8","article-title":"The effect of a reduction in alcohol consumption on blood pressure: A systematic review and meta-analysis","volume":"2","author":"Roerecke","year":"2017","journal-title":"Lancet Public Health"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/00004872-199205000-00014","article-title":"Persistent blood pressure increase induced by heavy smoking","volume":"10","author":"Groppelli","year":"1992","journal-title":"J. Hypertens."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1161\/01.CIR.90.1.248","article-title":"Mechanisms responsible for sympathetic activation by cigarette smoking in humans","volume":"90","author":"Grassi","year":"1994","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5586403","DOI":"10.1155\/2023\/5586403","article-title":"Comparative Analysis of Hypertension Guidelines: Unveiling Consensus and Discrepancies in Lifestyle Modifications for Blood Pressure Control","volume":"2023","author":"Wang","year":"2023","journal-title":"Cardiol. Res. Pract."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1161\/HYPERTENSIONAHA.120.15781","article-title":"Adherence to Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension","volume":"77","author":"Parati","year":"2021","journal-title":"Hypertension"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1097\/HJH.0000000000000222","article-title":"Factors involved in the discontinuation of antihypertensive drug therapy","volume":"32","author":"Mancia","year":"2014","journal-title":"J. Hypertens."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/HYPERTENSIONAHA.118.11308","article-title":"Initial Antihypertensive Treatment Strategies and Therapeutic Inertia","volume":"72","author":"Rea","year":"2018","journal-title":"Hypertension"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"147032031988265","DOI":"10.1177\/1470320319882656","article-title":"Effects of dual blockade in heart failure and renal dysfunction: Systematic review and meta-analysis","volume":"20","author":"Silva","year":"2019","journal-title":"J. Renin-Angiotensin-Aldosterone Syst."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients","volume":"359","author":"Jamerson","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1097\/HJH.0b013e328348345d","article-title":"Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension","volume":"29","author":"Matsuzaki","year":"2011","journal-title":"J. Hypertens."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/hr.2014.144","article-title":"Combination therapy of hypertension in the elderly: A subgroup analysis of the Combination of OLMesartan and a calcium channel blocker or diuretic in Japanese elderly hypertensive patients trial","volume":"38","author":"Ogihara","year":"2014","journal-title":"Hypertens. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/jgs.18683","article-title":"Association of a calcium channel blocker and diuretic prescribing cascade with adverse events: A population-based cohort study","volume":"72","author":"Rochon","year":"2023","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/1573402114666180918102735","article-title":"Three Generations of \u03b2-blockers: History, Class Differences and Clinical Applicability","volume":"15","author":"Ceron","year":"2019","journal-title":"Curr. Hypertens. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1097\/HJH.0000000000000614","article-title":"Effects of blood pressure-lowering on outcome incidence in hypertension","volume":"33","author":"Thomopoulos","year":"2015","journal-title":"J. Hypertens."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/HJH.0000000000000378","article-title":"Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials","volume":"32","author":"Thomopoulos","year":"2014","journal-title":"J. Hypertens."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","author":"The","year":"2002","journal-title":"JAMA: J. Am. Med. Assoc."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): A randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1161\/HYPERTENSIONAHA.122.19744","article-title":"Blood Pressure and Cardiorenal Outcomes with Finerenone in Chronic Kidney Disease in Type 2 Diabetes","volume":"79","author":"Ruilope","year":"2022","journal-title":"Hypertension"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Chua, S.-K., Lai, W.-T., Chen, L.-C., and Hung, H.-F. (2021). The Antihypertensive Effects and Safety of LCZ696 in Patients with Hypertension: A Systemic Review and Meta-Analysis of Randomized Controlled Trials. J. Clin. Med., 10.","DOI":"10.3390\/jcm10132824"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.jacc.2023.12.024","article-title":"2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure with Reduced Ejection Fraction","volume":"83","author":"Maddox","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","article-title":"\u03b2 blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): A randomised, double-blind, placebo-controlled, multicentre trial","volume":"393","author":"Villanueva","year":"2019","journal-title":"Lancet"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/S0140-6736(14)60685-1","article-title":"Blood pressure and incidence of twelve cardiovascular diseases: Lifetime risks, healthy life-years lost, and age-specific associations in 1\u00b725 million people","volume":"383","author":"Rapsomaniki","year":"2014","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e004152","DOI":"10.1161\/JAHA.116.004152","article-title":"Left Ventricular Hypertrophy Regression During Antihypertensive Treatment in an Outpatient Clinic (the Campania Salute Network)","volume":"6","author":"Izzo","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0733-8651(02)00004-8","article-title":"The heart, kidney, and brain as target organs in hypertension","volume":"20","author":"Mensah","year":"2002","journal-title":"Cardiol. Clin."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/sj.jhh.1002145","article-title":"Renal resistive index and cardiovascular organ damage in a large population of hypertensive patients","volume":"21","author":"Tedesco","year":"2007","journal-title":"J. Hum. Hypertens."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41440-020-0521-2","article-title":"Concurrent analogous organ damage in the brain, eyes, and kidneys in malignant hypertension: Reversible encephalopathy, serous retinal detachment, and proteinuria","volume":"44","author":"Mishima","year":"2020","journal-title":"Hypertens. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1161\/HYPERTENSIONAHA.123.21356","article-title":"Hypertension, Neurodegeneration, and Cognitive Decline","volume":"81","author":"Pacholko","year":"2024","journal-title":"Hypertension"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"72B","DOI":"10.1016\/S0828-282X(06)70990-4","article-title":"Arterial stiffness or endothelial dysfunction as a surrogate marker of vascular risk","volume":"22","author":"Anderson","year":"2006","journal-title":"Can. J. Cardiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"232","DOI":"10.5603\/ah.96896","article-title":"The overall echogenicity (GSM) of carotid intima-media complex shows a positive correlation with arterial stiffness in hypertensive patients","volume":"27","author":"Natale","year":"2023","journal-title":"Arter. Hypertens."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/1573402115666191011111402","article-title":"Resistant Hypertension: Novel Insights","volume":"16","author":"Lamirault","year":"2020","journal-title":"Curr. Hypertens. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1111\/imj.16189","article-title":"Revisiting resistant hypertension: A comprehensive review","volume":"53","author":"Chan","year":"2023","journal-title":"Intern. Med. J."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Dybiec, J., Krzemi\u0144ska, J., Radzioch, E., Szlagor, M., Wronka, M., M\u0142ynarska, E., Rysz, J., and Franczyk, B. (2023). Advances in the Pathogenesis and Treatment of Resistant Hypertension. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241612911"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/IBPC.S264057","article-title":"Evidence of Nonadherence in Cases of Pseudoresistant Hypertension","volume":"14","author":"Zanatta","year":"2021","journal-title":"Integr. Blood Press. Control"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"E126","DOI":"10.1002\/ccd.26030","article-title":"Influence of pseudo-resistance on the effect of renal denervation on 24-h ambulatory blood pressure levels","volume":"86","author":"Lambert","year":"2015","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"924","DOI":"10.4103\/jfmpc.jfmpc_1416_23","article-title":"An assessment of treatment compliance using the Morisky scale-8 tool in adult hypertensive patients of Eastern India","volume":"13","author":"Kishor","year":"2024","journal-title":"J. Fam. Med. Prim. Care"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e13645","DOI":"10.2196\/13645","article-title":"Smartphone Apps to Support Self-Management of Hypertension: Review and Content Analysis","volume":"7","author":"Alessa","year":"2019","journal-title":"JMIR Mhealth Uhealth"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"R245","DOI":"10.1152\/ajpregu.00647.2009","article-title":"Translational medicine: The antihypertensive effect of renal denervation","volume":"298","author":"DiBona","year":"2010","journal-title":"Am. J. Physiol.-Regul. Integr. Comp. Physiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/S0140-6736(21)00788-1","article-title":"Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): A randomised, multicentre, single-blind, sham-controlled trial","volume":"397","author":"Azizi","year":"2021","journal-title":"Lancet"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/S0140-6736(20)30554-7","article-title":"Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): A multicentre, randomised, sham-controlled trial","volume":"395","author":"Kario","year":"2020","journal-title":"Lancet"},{"key":"ref_57","first-page":"e677","article-title":"Durability of blood pressure reduction after ultrasound renal denervation: Three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial","volume":"18","author":"Rader","year":"2022","journal-title":"EuroIntervention J. EuroPCR Collab. Work. Group Interv. Cardiol. Eur. Soc. Cardiol."},{"key":"ref_58","first-page":"89","article-title":"Review and meta-analysis of renal artery damage following percutaneous renal denervation with radiofrequency renal artery ablation","volume":"16","author":"Townsend","year":"2020","journal-title":"EuroIntervention J. EuroPCR Collab. Work. Group Interv. Cardiol. Eur. Soc. Cardiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1093\/ndt\/gfx088","article-title":"Renal safety of catheter-based renal denervation: Systematic review and meta-analysis","volume":"32","author":"Sanders","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1016\/j.jcin.2021.09.020","article-title":"Renal Denervation for Hypertension","volume":"14","author":"Ahmad","year":"2021","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1097\/HJH.0b013e3282a9be30","article-title":"Aldosterone excess and resistance to 24-h blood pressure control","volume":"25","author":"Pimenta","year":"2007","journal-title":"J. Hypertens."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/ajh\/hpac124","article-title":"The Nonsteroidal Mineralocorticoid-Receptor-Antagonist Finerenone in Cardiorenal Medicine: A State-of-the-Art Review of the Literature","volume":"36","author":"Georgianos","year":"2023","journal-title":"Am. J. Hypertens."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone\u2019s Antifibrotic Activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/FJC.0000000000000366","article-title":"Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy","volume":"67","author":"Grune","year":"2016","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/HJH.0000000000003330","article-title":"Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes","volume":"41","author":"Agarwal","year":"2023","journal-title":"J. Hypertens."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/ckj\/sfac234","article-title":"A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease","volume":"16","author":"Agarwal","year":"2023","journal-title":"Clin. Kidney J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/bph.16247","article-title":"Taming resistant hypertension: The promise of novel pharmacologic approaches and renal denervation","volume":"181","author":"Azzam","year":"2023","journal-title":"Br. J. Pharmacol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1161\/HYPERTENSIONAHA.110.161653","article-title":"GPR30 Expression Is Required for the Mineralocorticoid Receptor\u2013Independent Rapid Vascular Effects of Aldosterone","volume":"57","author":"Gros","year":"2011","journal-title":"Hypertension"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","article-title":"Effects of a Novel Aldosterone Synthase Inhibitor for Treatment of Primary Hypertension","volume":"124","author":"Calhoun","year":"2011","journal-title":"Circulation"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/jch.12051","article-title":"Study of Aldosterone Synthase Inhibition as an Add-On Therapy in Resistant Hypertension","volume":"15","author":"Karns","year":"2012","journal-title":"J. Clin. Hypertens."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1161\/HYPERTENSIONAHA.116.07716","article-title":"Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2)","volume":"69","author":"Bogman","year":"2017","journal-title":"Hypertension"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"101918","DOI":"10.1016\/j.cpcardiol.2023.101918","article-title":"Baxdrostat: A Novel Aldosterone Synthase Inhibitor for Treatment Resistant Hypertension","volume":"48","author":"Dogra","year":"2023","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/jama.2023.16029","article-title":"Aldosterone Synthase Inhibition with Lorundrostat for Uncontrolled Hypertension","volume":"330","author":"Laffin","year":"2023","journal-title":"JAMA"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1001\/jama.2023.17087","article-title":"A New Dawn for Aldosterone as a Therapeutic Target in Hypertension","volume":"330","author":"Williams","year":"2023","journal-title":"JAMA"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Gallo, G., Volpe, M., and Savoia, C. (2022). Endothelial Dysfunction in Hypertension: Current Concepts and Clinical Implications. Front. Med., 8.","DOI":"10.3389\/fmed.2021.798958"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.niox.2018.06.004","article-title":"Asymmetric dimethylarginine (ADMA) as an important risk factor for the increased cardiovascular diseases and heart failure in chronic kidney disease","volume":"78","author":"Liu","year":"2018","journal-title":"Nitric Oxide"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4161\/cam.2.3.6819","article-title":"The DDAH\/ADMA pathway is a critical regulator of NO signalling in vascular homeostasis","volume":"2","author":"Fiedler","year":"2014","journal-title":"Cell Adhes. Migr."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1161\/ATVBAHA.110.222638","article-title":"Dimethylarginine Dimethylaminohydrolase-1 Is the Critical Enzyme for Degrading the Cardiovascular Risk Factor Asymmetrical Dimethylarginine","volume":"31","author":"Hu","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1096\/fj.201800499R","article-title":"Neuropilin-1 maintains dimethylarginine dimethylaminohydrolase 1 expression in endothelial cells, and contributes to protection from angiotensin II\u2013induced hypertension","volume":"33","author":"Wang","year":"2018","journal-title":"FASEB J."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.3390\/jcm4061293","article-title":"Role of Neuropilin-1 in Diabetic Nephropathy","volume":"4","author":"Bondeva","year":"2015","journal-title":"J. Clin. Med."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Domingues, A., and Fantin, A. (2021). Neuropilin 1 Regulation of Vascular Permeability Signaling. Biomolecules, 11.","DOI":"10.3390\/biom11050666"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1161\/HYPERTENSIONAHA.122.19430","article-title":"Novel Pharmacological Approaches in the Treatment of Hypertension: A Focus on RNA-Based Therapeutics","volume":"80","author":"Addison","year":"2023","journal-title":"Hypertension"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nrneph.2011.29","article-title":"Limitations of angiotensin inhibition","volume":"7","author":"Nobakht","year":"2011","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"f360","DOI":"10.1136\/bmj.f360","article-title":"Efficacy and safety of dual blockade of the renin-angiotensin system: Meta-analysis of randomised trials","volume":"346","author":"Makani","year":"2013","journal-title":"BMJ"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1161\/HYPERTENSIONAHA.119.12703","article-title":"Strong and Sustained Antihypertensive Effect of Small Interfering RNA Targeting Liver Angiotensinogen","volume":"73","author":"Uijl","year":"2019","journal-title":"Hypertension"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2208391","article-title":"Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension","volume":"389","author":"Desai","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1001\/jama.2024.0728","article-title":"RNA Interference with Zilebesiran for Mild to Moderate Hypertension","volume":"331","author":"Bakris","year":"2024","journal-title":"JAMA"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1161\/01.HYP.0000101688.17370.87","article-title":"Blood Pressure Lowering in Essential Hypertension with an Oral Renin Inhibitor, Aliskiren","volume":"42","author":"Stanton","year":"2003","journal-title":"Hypertension"}],"container-title":["Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3271\/12\/4\/53\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:10:26Z","timestamp":1760112626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3271\/12\/4\/53"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,4]]},"references-count":91,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["medsci12040053"],"URL":"https:\/\/doi.org\/10.3390\/medsci12040053","relation":{},"ISSN":["2076-3271"],"issn-type":[{"value":"2076-3271","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,4]]}}}